Molecular and cellular aspects of nicotine abuse

Neuron

Volumn 16, Issue 5, 1996, Pages 905-908

  Dani, John A ^a   Heinemann, Steve ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NICOTINE; NICOTINIC RECEPTOR;

DOPAMINE RELEASE; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REWARD; SHORT SURVEY; SMOKING; SMOKING CESSATION; VENTRAL TEGMENTUM;

EID: 0029953564     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(00)80112-9     Document Type: Review

References (25)

1. Benowitz, N.L., Porchet, H., and Jacob, P., III (1989). Prog. Brain Res. 79, 279-287.
2. Calabresi, P., Lacey, M.G., and North, R.A. (1989). Br. J. Pharmacol. 98, 135-140.
3. Changeux, J.-P., Devillers-Thiery, A., and Chemouilli, P. (1984). Science 225, 1335-1345.
4. Clarke, P.B.S. (1991). In Effects of Nicotine on Biological Systems, F. Adlkofer and K. Thurau, eds. (Basel, Switzerland: Birkhäuser Verlag), pp. 285-294.
5. Corrigall, W.A., and Coen, K.M. (1989). Psychopharmacology 99, 473-478.
6. Corrigall, W.A., Franklin, K.B., Coen, K.M., and Clarke, P.B. (1992). Psychopharmacology 107, 285-289.
7. Fowler, J.S., Volkow, N.D., Wang, G.-J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., Wolf, A.P., Warner, D., Zezulkova, I., and Cilento, R. (1996). Nature 379, 733-736.
8. Giros, B., Jaber, M., Jones, S.R., Wightman, R.M., and Caron, M.G. (1996). Nature 379, 606-612.
9. Goldberg, S.R., and Henningfield, J.E. (1988). Pharmacol. Biochem. Behav. 30, 227-234.
10. Henningfield, J.E., Stapleton, J.M., Benowitz, N.L., Grayson, R.F., and London, E.D. (1993). Drug Alcohol Depend. 33, 23-29.
11. Hulihan-Giblin, B.A., Lumpkin, M.D., and Kellar, K.J. (1990). J. Pharmacol. Exp. Ther. 252, 21-25.
12. Koob, G.F. (1992). Trends Pharmacol. Sci. 13, 177-184.
13. Lester, R.A.J., and Dani, J.A. (1994). Neuropharmacology 33, 27-34.
14. Margiotta, J.F., Berg, D.K., and Dionne, V.E. (1987). Proc. Natl. Acad. Sci. USA 84, 8155-8159.
15. Marks, M.J., Grady, S.R., and Collins, A.C. (1993). J. Pharmacol. Exp. Ther. 266, 1268-1276.
16. Marks, M.J., Pauly, J.R., Gross, S.D., Deneris, E.S., Hermans-Borgmeyer, I., Heinemann, S.F., and Collins, A.C. (1992). J. Neurosci. 12, 2765-2784.
17. McGehee, D.S., and Role, L.W. (1995). Annu. Rev. Physiol. 57, 521-546.
18. Peng, X., Gerzanich, V., Anand, R., Whiting, P.J., and Lindstrom, J. (1994). Mol. Pharmacol. 46, 523-530.
19. Peto, R., Lopez, A.D., Boreham, J., Thun, M., and Heath, C. (1992). Lancet 339, 1268-1278.
20. Russell, M.A.H. (1989). Prog. Brain Res. 79, 289-302.
21. Schelling, T.C. (1992). Science 255, 430-433.
22. Shoaib, M., Stolerman, I.P., and Kumar, R.C. (1994). Psychopharmacology 113, 445-452.
23. Stolerman, I.P., and Shoaib, M. (1991). Trends Pharmacol. Sci. 12, 466-473.
24. Wada, E., Waka, K., Boulter, J., Deneris, E., Heinemann, S., Patrick, J., and Swanson, L.W. (1989). J. Comp. Neurol. 284, 314-335.
25. Wonnacott, S. (1990). Trends Pharmacol. Sci. 11, 216-218.